Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study-Reference-Cited by-同舟云学术

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Published:2018-03-17 Issue: Volume: Page:annrheumdis-2017-212687
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Mease Philip^ORCID,van der Heijde Désirée,Landewé Robert,Mpofu Shephard,Rahman Proton,Tahir Hasan,Singhal Atul,Boettcher Elke,Navarra Sandra,Meiser Karin,Readie Aimee,Pricop Luminita,Abrams Ken

Funder

Novartis Pharma AG, Switzerland

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference33 articles.

1. Psoriatic arthritis: epidemiology, clinical features, course, and outcome;Gladman;Ann Rheum Dis,2005

2. Classification criteria for psoriatic arthritis: development of new criteria from a large international study;Taylor;Arthritis Rheum,2006

3. Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey;Kavanaugh;Rheumatol Ther,2016

4. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study;McHugh;Rheumatology,2003

5. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience;Kane;Rheumatology,2003

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

2. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects;Drug Design, Development and Therapy;2024-08

3. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

4. Evaluating the inhibition of IL-17A and TNFα in a cartilage explant model cultured with Th17-derived cytokines;Journal of Translational Autoimmunity;2024-06

5. CHOP-mediated IL-23 overexpression does not drive colitis in experimental spondyloarthritis;Scientific Reports;2024-05-29